45
Insulin Therapy Insulin Therapy and and GLP-1 analogues GLP-1 analogues Dr. Spurgeon Dept of Endocrinology, Christian Medical College, Vellore

Insulin Therapy and GLP-1 analogues

  • Upload
    tomai

  • View
    36

  • Download
    0

Embed Size (px)

DESCRIPTION

Insulin Therapy and GLP-1 analogues. Dr. Spurgeon Dept of Endocrinology, Christian Medical College, Vellore. 100. 80. 60.  -cell function ( % ). 40. 20. 0. -12. -6. 0. 6. 12. Years. Progressive Beta Cell failure in Type II Diabetes Mellitus. - PowerPoint PPT Presentation

Citation preview

Page 1: Insulin Therapy and GLP-1 analogues

Insulin TherapyInsulin Therapyandand

GLP-1 analogues GLP-1 analogues

Dr. Spurgeon

Dept of Endocrinology,

Christian Medical College, Vellore

Page 2: Insulin Therapy and GLP-1 analogues

-12-12 -6-6 00 66 121200

2020

4040

6060

8080

100100

-ce

ll fun

ctio

n (%

)-

cell f

unct

ion

(%)

Years

Years

Progressive Beta Cell failure in Type II Diabetes Mellitus

Page 3: Insulin Therapy and GLP-1 analogues

Stimulates entry of amino acids into cells, enhancing protein synthesis

Enhances fat storage (lipogenesis) and prevents mobilization of fat for energy (Lipolysis and Ketogenesis)

Stimulates entry of glucose into cells for utilization as energy source

Promotes storage of glucose as glycogen in muscle and liver cells (glycogenesis)

What are the anabolic effects of Insulin?What are the anabolic effects of Insulin?

Page 4: Insulin Therapy and GLP-1 analogues

“The Magnificent Seven”

When should Insulin be used in When should Insulin be used in Type 2 diabetes mellitus?Type 2 diabetes mellitus?

Page 5: Insulin Therapy and GLP-1 analogues

1. Type 2 diabetes not controlled with maximal doses of Oral Hypoglycaemic agents

What do you mean by maximal doses of OHAs?

Metformin 2500/3000mg a day

+

Glipizide 20mg/glibenclemide15-20mg/day

Gliciazide 320mg/ Glimepride 6-8mg/day

+

Rosiglitazone 8mg/ Pioglitazone 45mg/day

When should Insulin be used in When should Insulin be used in Type 2 diabetes mellitus?Type 2 diabetes mellitus?

Page 6: Insulin Therapy and GLP-1 analogues

2. Type 2 diabetes during periods of physiological

stress (surgery, infection)

Continue OHAs simultaneously.

Stop metformin in case of severe infections or

impending reduction in renal perfusion

When should Insulin be used in When should Insulin be used in Type 2 diabetes mellitus?Type 2 diabetes mellitus?

Page 7: Insulin Therapy and GLP-1 analogues

3. Pregestational diabetes

Metformin may be continued

Discontinue other medications

When should Insulin be used in When should Insulin be used in Type 2 diabetes mellitus?Type 2 diabetes mellitus?

Page 8: Insulin Therapy and GLP-1 analogues

4. Use of parenteral nutrition

or high-caloric supplements

Indications of Insulin therapy?Indications of Insulin therapy?

Page 9: Insulin Therapy and GLP-1 analogues

5. Diabetic ketoacidosis (DKA)/Hyperosmolar

hyperglycemic nonketotic syndrome (HHNS)

Indications of Insulin therapy?Indications of Insulin therapy?

Page 10: Insulin Therapy and GLP-1 analogues

6. Progressive complications:

proliferative retinopathy/maculopathy, progressive or painful neuropathy

For rapid control and tighter adjustment

Indications of Insulin therapy?Indications of Insulin therapy?

Page 11: Insulin Therapy and GLP-1 analogues

7. Chronic Renal Failure

For all above a creatinine of 4.0mg/dl

Cutoffs for other OHAs:-

Metformin: 1.5mg/dl

Glimeperide/Glibenclemide: 2.0mg/dl

Glipizide: 2.5mg/dl

Pioglitazone/Rosiglitazone: 4.0mg/dl

Indications of Insulin therapy?Indications of Insulin therapy?

Page 12: Insulin Therapy and GLP-1 analogues

What is the normal insulin secretory pattern?

Basal

Bolus

Page 13: Insulin Therapy and GLP-1 analogues

How does one classify the types of insulin?How does one classify the types of insulin?

Generally classified according to peak effect and duration of action

Short acting: regular/ Lispro /Aspart

Intermediate acting: NPH/ Lente

Premixed:(30/70), (50/50)

Page 14: Insulin Therapy and GLP-1 analogues

What are the types of Insulin ?What are the types of Insulin ?

• Short acting

• Intermediate acting

• Long acting

• Analogs

: Regular insulin

: Lente insulin

NPH insulin

: Ultralente

Short acting : Lispro, Aspart Long acting : Glargine

Page 15: Insulin Therapy and GLP-1 analogues

What is the time action profile of different types of insulins?

Page 16: Insulin Therapy and GLP-1 analogues

What are the types What are the types of insulin regimens?of insulin regimens?

• Premixed regimen

• Split mix regimen

• Basal bolus regime (multidose)

• Bedtime dosing alone (NPH/Lente/Glargine)

• Infusion

Page 17: Insulin Therapy and GLP-1 analogues

Premixed insulin:actionPremixed insulin:action

Page 18: Insulin Therapy and GLP-1 analogues

Premixed insulinPremixed insulin

• Premixed(30/70): Regular: 30 % NPH : 70%

• Premixed (50/50): Regular 50% NPH 50%

• Premixed Analogs Biphasic insulin aspart (30/70) 30% : Aspart 70% : protaminated aspart

Page 19: Insulin Therapy and GLP-1 analogues

Insulin Therapy RegimensInsulin Therapy Regimens

Usual starting dose: 0.5-1.0 unit/kg/day

Page 20: Insulin Therapy and GLP-1 analogues

Premixed insulinPremixed insulin

• Dose adjustment:

• The fasting sugar depends on the night dose of insulin • The post breakfast sugar depends on the

morning dose of insulin

• Rough calculation increase the insulin by one unit to reduce the sugars by 25mg/dl

Page 21: Insulin Therapy and GLP-1 analogues

Self Monitoring is crucialSelf Monitoring is crucial

Glucometers

At least 6-8 times a week ideally

Page 22: Insulin Therapy and GLP-1 analogues

Premixed insulinPremixed insulin Advantages • more accurate dosing

• lesser injections

• Pen devices administer premixed forms

Disadvantages • Fine tuning may not be possible

• Strict meal pattern

• Nocturnal hypoglycemia

• May need “diet changes for insulin” rather than “insulin changes for diet”

Page 23: Insulin Therapy and GLP-1 analogues

Split-mixed insulinSplit-mixed insulin

• Common combinations: Short acting plus intermediate acting

in a syringe:-

Regular + NPH

Page 24: Insulin Therapy and GLP-1 analogues

How to adjust insulin doses in a split mixHow to adjust insulin doses in a split mix

NPHRegular

Increase regular insulin

Regular

meal

Page 25: Insulin Therapy and GLP-1 analogues

How to adjust insulin doses in a split mixHow to adjust insulin doses in a split mix

Regular

NPH

Reduce regular insulin

Regular

meal

Page 26: Insulin Therapy and GLP-1 analogues

How to adjust insulin doses in a How to adjust insulin doses in a split mix ?split mix ?

Regular

NPH

Increase NPH insulin

Peak action of NPH

meal

Page 27: Insulin Therapy and GLP-1 analogues

How to adjust insulin doses in How to adjust insulin doses in a split mix ?a split mix ?

Regular

NPHNPH

Regular

Reduce NPH insulin

Peak action of NPH

Meal

Page 28: Insulin Therapy and GLP-1 analogues

Split-mixed insulinSplit-mixed insulin

Advantages • Less hypoglycaemia, with fine tuning• More physiologic• Adjustable meal pattern

Disadvantages • More patient education required• Cumbersome mixing• Pen device not feasible if two injections are

planned for.

Page 29: Insulin Therapy and GLP-1 analogues

Bedtime NPH/GlargineBedtime NPH/Glargine

Continue daytime oral hypoglycaemic agents: especially sulphonylureas (The BIDS regimen)

Advantage: Once daily dosing Easy dose titration

Disadvantage: May need premeal bolus

Page 30: Insulin Therapy and GLP-1 analogues

NPHNPH

NPH

Page 31: Insulin Therapy and GLP-1 analogues

GlargineGlargine

Glargine

Page 32: Insulin Therapy and GLP-1 analogues

Bedtime Long- acting Bedtime Long- acting

Advantages • Single Daily dosing

Disadvantages • Suitable for only <15% of Type 2 Diabetes

Page 33: Insulin Therapy and GLP-1 analogues

Basal bolus Basal bolus regime(multidose)regime(multidose)

Rarely used in Type 2 Rarely used in type 2 diabetes

Page 34: Insulin Therapy and GLP-1 analogues

Starting insulin in type 2 diabetes - patient on full dose OHA

• Continue the OHA

• Start on insulin (approx 0.2 U/kg/day,morning 2/3, evening 1/3)

• Reassess control with SMBG & titrate dosage

• Consider adding short acting premeal bolus if uncontrolled PPBG

• Consider withdrawing sulphonylurea

Page 35: Insulin Therapy and GLP-1 analogues

Can Oral hypoglycaemic agents

be continued at the same time with insulin?

• Metformin Best continued if renal function is normal. May

reduce insulin requirements by 15-30%.• Adjunctive weight reducing effect

• Thiazolidinediones • May be continued with insulin. • Can reduce insulin requirements from 15-60% • Major issue of weight gain, accentuated by

insulin: 7.5%. 15%>5kg.

Page 36: Insulin Therapy and GLP-1 analogues

Can Oral hypoglycaemic agents

be continued at the same time with insulin?

• Sulphonylureas

• Glimeperide: doses of 2-4mg a day have a peripheral GLUT-4 activity reducing insulin requirement by 10-20%.

• Glipizide and Glibenclemide can reduce insulin requirements by 5-15%.

• Unpredictable- recommended previously in those with high C-peptide levels

Page 37: Insulin Therapy and GLP-1 analogues

Used in situations like Used in situations like DKA, immediate control of sugars DKA, immediate control of sugars

monitor sugars more frequentlymonitor sugars more frequentlymonitor potassiummonitor potassiumover lap with long acting insulin over lap with long acting insulin

InfusionInfusion

Page 38: Insulin Therapy and GLP-1 analogues

GLP-1 AnaloguesGLP-1 Analogues

• accounted for by following effects:

• – stimulation of insulin secretion

• – inhibition of glucagon release

• – delay of gastric emptying

• – increase of insulin sensitivity

Page 39: Insulin Therapy and GLP-1 analogues

• Stimulates insulin gene expression

• Stimulates insulin biosynthesis

• Stimulates -cell proliferation and survival

• Stimulates differentiation of exocrine cells or islet

• precusors toward -cell phenotype

Page 40: Insulin Therapy and GLP-1 analogues

When do you start?When do you start?

• As mono or combination therapy

• Obese type 2 Diabetics

• Along with oral drugs.

Page 41: Insulin Therapy and GLP-1 analogues

Development of Exenatide: An Development of Exenatide: An Incretin MimeticIncretin Mimetic

• Exenatide (Exendin-4)• – Synthetic version of salivary protein• found in the Gila monster• – Approximately 50% identity with• human GLP-1• • Binds to known human GLP-1• receptors on cells in vitro• • Resistant to DPP-IV inactivation

Page 42: Insulin Therapy and GLP-1 analogues

DOSAGE AND ADMINISTRATIONDOSAGE AND ADMINISTRATION

• Inject subcutaneously within 60 minutes prior to morning and evening meals (or before the two main meals of the day, approximately 6 hours or more apart.

• Initiate at 5 mcg per dose twice daily; increase to 10 mcg twice daily after 1 month based on clinical response .

• Initiation with 5 mcg reduces the incidence and severity of gastrointestinal side effects.

Page 43: Insulin Therapy and GLP-1 analogues

• BYETTA is supplied as 250 mcg/mL exenatide in:

• • 5 mcg per dose, 60 doses, 1.2 mL prefilled pen

• • 10 mcg per dose, 60 doses, 2.4 mL prefilled pen

Page 44: Insulin Therapy and GLP-1 analogues

Contraindicated--Contraindicated--

• Type 1 DM

• History of pancreatic disease

• Should not be used in patients with severe renal impairment (creatinine clearance < 30 mL/min).

• Severe GI problems

• Hypersenitivity to drug

Page 45: Insulin Therapy and GLP-1 analogues

Insulin administration is suitably as premixed Insulin administration is suitably as premixed fashion for most type 2 diabetes. Split-mix may be fashion for most type 2 diabetes. Split-mix may be required in a subset. required in a subset.

The neccessity of self blood glucose monitoring as a The neccessity of self blood glucose monitoring as a accessory is emphasized. accessory is emphasized.

Summarizing……..Summarizing……..